Beijing Leadman Biochemistry Co., Ltd. Class A

Beijing Leadman Biochemistry Co., Ltd. Class A

SSZSE:300289
5.94
CNY
-0.09
(-1.49%)
0.01EPS
3.30BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.9
1.38
1.73
1.3
1.34
1.56
1.63
1.11
1.26
1.25
0.9
0.69
0.57
0.89
Basic EPS, GAAP
0.29
0.33
0.4
0.17
0.17
0.1
0.02
-0.12
0.05
-0.1
0.03
-0.14
-0.04
-0.02
Free Cash Flow per Basic Share
-0.16
-0.08
0.39
0.14
0.26
0.16
0.31
0.25
0.17
0.12
0.22
0.06
0.02
- -
Dividend per Share
0.1
0.12
0.14
0.12
0.03
0.05
0.02
0.02
- -
0.02
- -
0.01
- -
- -
Book Value per Share
2.22
2.45
2.79
2.93
3.09
3.09
3.13
3
3.37
3.18
3.2
3.06
3.01
3.03
Tangible Book Value per Share
2.15
1.94
2.33
2.48
2.67
2.61
2.5
2.39
2.95
2.82
2.88
2.87
2.84
1.37
Basic Weighted Avg Shares
382
389
393
410
430
420
315
425
448
563
511
536
575
544
Sales/Revenue/Turnover
344
537
682
533
576
655
515
472
564
706
462
370
326
486
Operating Margin (%)
35.11
33.93
32.61
22.12
23.39
16.34
11.15
11.5
13.38
6.89
8.3
-6.64
-7.21
3.82
Depreciation Expense
17
45
52
43
40
41
44
52
59
63
63
59
49
- -
Net Income, GAAP
110
128
157
70
73
40
6
-51
22
-56
15
-75
-23
-9
Effective Tax Rate (%)
14.18
14.35
14.8
14.98
15.19
14.39
11.26
- -
19.76
- -
7.63
- -
- -
57.1
Profit Margin (%)
32.03
23.89
23.06
13.06
12.69
6.18
1.22
-10.81
3.97
-7.97
3.32
-20.29
-7.04
-1.83
Working Capital
370
246
372
531
615
574
578
523
1,100
957
999
1,026
1,015
1,437
LT Debt
219
80
- -
64
20
- -
- -
13
10
8
5
1
1
976
Total Equity
851
1,093
1,260
1,337
1,425
1,437
1,450
1,379
1,978
1,780
1,805
1,719
1,671
2,122
Return on Invested Capital (%)
10.26
11.79
12.65
5.69
6.61
4.08
1.9
- -
3
- -
1.34
- -
- -
0.3
Return on Capital (%)
10.72
11.01
11.19
3.77
3.45
1.53
-0.77
- -
-0.03
- -
0.47
- -
- -
-0.93
Return on Common Equity (%)
13.66
14.13
14.62
5.74
5.73
3.09
0.48
-3.95
1.45
-3.16
0.88
-4.41
-1.39
-0.54

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
3
3
6
LT Borrowings
- -
- -
976
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
544
544
544
Market Capitalization
3,656
3,019
3,297

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,109
1,105
1,875
Cash, Cash Equivalents & STI
913
916
575
Accounts Receivable, Net
85
84
386
Inventories
88
85
101
Total Current Liabilities
79
75
438
Payables & Accruals
- -
- -
- -
ST Debt
3
3
6
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.68%
5.46%
-2.78%
Free Cash Flow
-7.08%
-22.35%
-65.12%
Net Income, GAAP
-236.92%
-256.26%
-69.4%
Sales/Revenue/Turnover
-5.14%
-4.3%
-11.86%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
95
94
93
88
370
2025
79
82
- -
74
326
2026
70
81
260
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.01
- -
-0.14
-0.14
2025
- -
-0.01
- -
-0.03
-0.04
2026
-0.01
-0.01
0.03
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.01
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Ouyang Xu
Full Time Employees
420
Sector
Health technology
Industry
Medical specialties
Address
No.5 Xinghai Road Beijing BE China 100176
IPO Date
Feb 7, 2012
Business
Beijing Leadman Biochemistry Co., Ltd. operates primarily as a biopharmaceutical company specializing in the research, development, manufacturing, and sales of biochemical products. Its core product categories include active pharmaceutical ingredients (APIs); intermediates; biochemicals, such as amino acids, nucleotides, and organic acids; and specialty reagents. The company provides products to multiple end markets including pharmaceuticals, food and beverages, cosmetics, and agriculture. Founded in 2000 and headquartered in Beijing, China, Beijing Leadman Biochemistry serves clients domestically and internationally. Recently, Beijing Leadman Biochemistry has focused on strategic business expansions and innovation in its biochemical segment to enhance product portfolio and market reach. Over the last 1-2 years, the company has launched new product lines targeting high-tech biochemical compounds and invested in partnerships aimed at expanding its biotechnology capabilities. These initiatives are aligned with broader efforts to strengthen its R&D infrastructure and enhance competitive positioning in both domestic and global biochemical markets. The company's operations span the biochemical industry with business segments including pharmaceutical-grade raw materials production, specialty biochemical manufacturing, and biotechnological service offerings. Beijing Leadman Biochemistry's target customers include pharmaceutical manufacturers, research institutions, and industrial biotechnology enterprises. Its geographic footprint includes China as a primary market along with growing exports to Asia-Pacific and other international regions. The company may operate several subsidiaries and maintains a focus on innovation-driven growth in the biochemistry sector.